SSRIs associated with decreased risk of hepatocellular carcinoma: A population-based case-control study

Hsiang Lin Chan, Wei Che Chiu, Vincent Chin Hung Chen, Kuo You Huang, Tsu Nai Wang, Yena Lee, Roger S. McIntyre, Tsai Ching Hsu, Charles Tzu Chi Lee, Bor Show Tzang*

*此作品的通信作者

研究成果: 雜誌貢獻期刊論文同行評審

25 引文 斯高帕斯(Scopus)

摘要

Background: Hepatocellular carcinoma (HCC) is the second leading cancer-related cause of mortality worldwide. Antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), are commonly used worldwide. Available evidence investigating the association between SSRIs use and HCC risk is limited. Objective: The present study aimed to investigate if the effect of all kinds of SSRIs on HCC was the same or not using population-based study. Methods: The nationwide population-based study herein using Taiwan's National Health Insurance Research Database included a total of 59 859 cases with HCC and 285 124 matched controls. Conditional logistic regression analyses were adjusted for confounding variables. Results: All common kinds of SSRIs including fluoxetine, sertraline, paroxetine, citalopram, escitalopram, and fluvoxamine were associated with lower HCC risk, and the findings were dose-dependent (eg, fluoxetine: 1-28 DDD [defined daily dose]: adjusted odds ratio [aOR]: 0.81, 95% confidence interval [CI], 0.73-0.89; 29-365 DDD: aOR: 0.71, 95% CI, 0.64-0.79; and ≥366 DDD: aOR: 0.55, 95% CI, 0.45-0.67) (P for trend <.001). Conclusions: All kinds of SSRIs were associated with decreased risk of HCC.

原文英語
頁(從 - 到)187-192
頁數6
期刊Psycho-Oncology
27
發行號1
DOIs
出版狀態已發佈 - 2018 1月

ASJC Scopus subject areas

  • 實驗與認知心理學
  • 腫瘤科
  • 精神病學和心理健康

指紋

深入研究「SSRIs associated with decreased risk of hepatocellular carcinoma: A population-based case-control study」主題。共同形成了獨特的指紋。

引用此